Hologic's Fiscal Q1 2023 Earnings: A Ray of Hope in a Stormy Year
Hologic has managed to achieve impressive financial results in Fiscal Q1 2023.
avatar
Staff or Guest writer for The Dog of Wall Street.
2023-01-08 22:13

You know what they say: when the going gets tough, the tough get going. And boy, has Hologic (Nasdaq: HOLX) been going strong in Fiscal Q1 2023. Despite the bumpy year we had, the company reported preliminary revenue results of approximately $1 Billion, a decrease of only (27.0%) compared to the prior year period, or (25.1%) in constant currency. This exceeded the company's most recent revenue guidance range of $940 to $990 million, provided on October 31, 2022.
Hologic's Fiscal Q1 2023 Earnings: A Ray of Hope in a Stormy Year
But let's not forget the real miracle here: Hologic's Diagnostics and Surgical businesses both saw double-digit growth in constant currency, excluding COVID-19. The Diagnostics division reported organic growth of 15.8%, while the Surgical division saw organic growth of 14.7%. And the Molecular Diagnostics division had impressive growth of 24.5% in constant currency, excluding COVID-19. Talk about defying the odds!

And it looks like Hologic's Breast Health business is also making a comeback, with results ahead of the company's prior estimate for the quarter. This is great news, as the pandemic had a devastating impact on the breast health industry.

In addition to these impressive revenue results, Hologic expects non-GAAP diluted earnings per share (EPS) to be above the guidance range of $0.80 to $0.90 provided on October 31, 2022. This is just the cherry on top of a very delicious and successful Q1 2023 for the company.

So let's raise a glass (of hand sanitizer, of course) to Hologic. See press release here.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2023-01-08 22:13

avatar
About the Author
Staff or Guest writer for The Dog of Wall Street.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Is Tesla Back? Has TSLA Stock Finally Bottomed?
Tesla Stock Analysis: Robo Taxis to the Rescue?
By Mike Sakuraba | 2 weeks ago

2 Stocks to Buy During an April Pullback
Here are 2 stocks I’d buy during an April pullback.
By Mike Sakuraba | 2 weeks ago

TSM Stock: Is This The True Winner of the AI Race?
TSM’s stock has gained nearly 40% this year which is about half of NVIDIA has returned.
By Mike Sakuraba | 2 weeks ago

Best Proxy for Bitcoin: Coinbase or IBIT
In this article, we’ll compare the iShares Bitcoin Trust to Coinbase to see which is the best proxy for Bitcoin on the stock market.
By Mike Sakuraba | 3 weeks ago

2 Under the Radar AI Stocks to Buy
If you’re tired of reading about NVIDIA, consider these two AI stocks to add while the chip market cools off.
By Mike Sakuraba | 3 weeks ago

3 Bold Predictions for the Second Quarter
So here’s what I’m expecting for the second quarter and I’ll throw in a couple of bold predictions as well!
By Mike Sakuraba | 3 weeks ago

2 Stocks Cathie Wood Keeps Buying That You Should Too
In the world of retail investing, Cathie Wood and her Ark Invest fund are extremely polarizing.
By Mike Sakuraba | 4 weeks ago

2 Under the Radar Stocks to Buy Before Others
One of the keys to investing has always been to identify weaknesses in stocks before others. Buy it when everyone hates it and when everyone loves it you’ll reap the rewards. Sounds easy enough right?
By Mike Sakuraba | 4 weeks ago